Silexion Strong Tumor Growth Reduction in Preclinical Pancreatic Cancer Models

 

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further studies aim to evaluate its impact on metastases

https://www.globenewswire.com/news-release/2025/01/28/3016377/0/en/Silexion-Therapeutics-Reports-Strong-Tumor-Growth-Reduction-from-Systemic-Administration-of-SIL-204-in-Preclinical-Pancreatic-Cancer-Models.html